TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
Tumor response according to RECIST v1.1 (investigator assessment) in response-evaluable patients
创建时间：
2024-02-12
